Anne Borgman, MD

Home » Research » Advisory Councils » Anne Borgman, MD
Anne Borgman, MD

Anne Borgman, MD

Chief Medical Officer

Sutro Biopharma

Anne Borgman is a seasoned oncology drug development physician with 18 years of industry experience. She has a breadth and depth of experience in big pharma, small biotech, both the private and the public sector, with molecules ranging from antibodies to intravenous infusions to small molecules.

Dr. Borgman’s training was in Pediatric Hematology Oncology& Bone Marrow Transplantation at University of California, Los Angeles, David Geffen School of Medicine following a Residency at Baylor College of Medicine, Texas Children's Hospital.

Dr. Borgman joined Abbott Laboratories in Abbott Park, Illinois, at the global headquarters as part of a fellowship designed for physicians interested in drug development. Dr. Borgman also held a conjoint faculty position at The University of Chicago. After 8 years at Abbott Laboratories, where Anne ran the global drug development programs for the Oncology franchise, including industry liaison to the Oncology Drug Advisory Committee of the FDA and lead for Abbott's small molecule BCL-2 inhibitor in collaboration with Genentech (now Roche), she moved to the Bay Area and joinedHana Biosciences, a publically owned biotechnology oncology company, as the Chief Medical Officer. Dr. Borgman advanced the lead compound to an accelerated approval in second relapsed adult Acute Lymphoblastic Leukemia, and raised capital with the CEO; the primary investment partners were Deerfield Capital and Warburg-Pincus. Warburg-Pincus divested their portfolio of the biotech sector, at which time Hana, then Talon Therapeutics, was sold to Spectrum Pharma.

Dr. Borgman joined Kalobios as Chief Medical Officer, a private company turned public via Fidelity, and after the company switched its area of focus to respiratory diseases from hematology, Dr. Borgman joined Exelixis in 2012 where she and her team conducted 2 major, successful Phase 3 programs resulting in successful U.S. and European filings in RCC and HCC, as well as a successful Europeanfiling in MTC.

Dr. Borgman is now Vice President, Therapeutic Area Head, Hematology and Oncology at Jazz Pharmaceuticals.

Pin It on Pinterest

Scroll to Top